Acetylcysteine Solution, USP, is a bronchial mucolytic indicated as an adjuvant therapy for patients with certain lung diseases and also as an acetaminophen antidote when administered orally. The
Rigosertib, which targets dual pathways (PI-3K and PLK) critical to the growth of cancer cell, is at present in a Phase III study for the treatment of Myelodysplastic
The agreement signed with HVD Biotech Vertriebs (HVD), calls for HVD to distribute the AXP AutoXpress System and BioArchive System in 10 European countries and 13 Middle Eastern
First Coast will deploy RayStation at oncology in conventional radiation treatment planning, which will begin in the fourth quarter of 2012. The treatment will also include IMRT with
The ten founding companies include Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech and Sanofi. TransCelerate will work to identify and solve
Z-TECT platform is designed by adapting elements of nanotechnology with molecular detection and immunology to aid the research field. Z-TECT will help in the early detection of cancer
Florax DS is formulated using a strain of the probiotic yeast called Saccharomyces Cerevisiae to provide temporary relief from occasional diarrhea, bloating, cramping, and gas within four hours.
ShangPharma will use Harbour’s human immunoglobulin-gene transgenic mice in Shanghai facility to provide fully human antibody development services to its clients. Licensed under the agreement to produce H2L2
The randomized placebo-controlled, double-blinded FACT 2 study has enrolled 300 subjects who will be randomized 1:1 to administer carboplatin and paclitaxel plus fosbretabulin versus carboplatin and paclitaxel plus
Ganetespib is a potent inhibitor of heat shock protein 90 (Hsp90), a molecular chaperone which is required for the proper folding and activation of many cancer-promoting proteins. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.